US EditionSeaStar Q1 Results: QUELIMMUNE Sales Up Fourfold Sequentially, Company Now Targeting Adult Market
Summary by NewMediaWire
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
SeaStar Q1 Results: QUELIMMUNE Sales Up Fourfold Sequentially, Company Now Targeting Adult Market
By Meg Flippin Benzinga DETROIT, MICHIGAN - May 29, 2025 (NEWMEDIAWIRE) - SeaStar Medical Holding Corporation (NASDAQ: ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life, is seeing double-digit growth in sales of QUELIMMUNE, which drove revenues for the company in the first quarter of 2025. QUELIMMUNE is the company’s first FDA-approved produ…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
